1
|
Hu X, Akutsu Y, Suganami A, Qin W, Hanari N, Murakam K, Kano M, Usui A, Suito H, Takahashi M, Matsumoto Y, Otsuta R, Tamura Y, Matsubara H. Low-dose hyperthermia enhances the antitumor effects of chemotherapy in squamous cell carcinoma. Dis Esophagus 2017; 30:1-7. [PMID: 30052898 DOI: 10.1093/dote/dow026] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2016] [Indexed: 12/11/2022]
Abstract
Esophageal squamous cell carcinoma is a highly aggressive neoplasm and the sixth leading cause of global cancer-related death; the 5-year survival rate for esophageal cancer is only about 20%-25% for all stages. Therefore, improving the therapeutic effect is important. This study assessed whether low-dose hyperthermia (LDH) enhances the antitumor effects of chemotherapy. The antitumor effect of chemotherapy with/without LDH in the squamous cell carcinoma cell line SCCVII was evaluated. A comprehensive analysis was performed with real-time polymerase chain reaction (PCR) to study the hyperthermia-induced changes in the gene expression of SCCVII cell lines. In addition, the cytotoxic and apoptotic changes in the cells treated with LDH combined with/without 5-fluorouracil (5-FU) were measured. LDH combined with 5-FU (10 nM) strongly inhibited the cell growth of SCCVII, with flow cytometry showing an increased population of apoptotic cells. PCR showed that LDH promoted a 25.22-fold increase of p53 mRNA and 18.08-fold increase of Bax mRNA in vitro. MDR1 expression was decreased to 28.7% after LDH. This treatment can result in much higher efficacy of antitumor drugs. After LDH, the expressions of TS decreased to 12.06%, OPRT increased by 4.17-fold, and DPD did not change (1.03-fold). This transformations will induce susceptibility to 5-FU. LDH may be a useful enhancer of chemotherapy drugs for squamous cell carcinoma.
Collapse
Affiliation(s)
- X Hu
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Akutsu
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - A Suganami
- Departments of Bioinformatics, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - W Qin
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - N Hanari
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - K Murakam
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - M Kano
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - A Usui
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - H Suito
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - M Takahashi
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Matsumoto
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - R Otsuta
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Tamura
- Departments of Bioinformatics, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - H Matsubara
- Departments of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| |
Collapse
|